Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response : challenges, Obstacles and Future Perspectives
Candiota Silveira, Ana Paula (Universitat Autònoma de Barcelona)
Arús i Caraltó, Carles (Universitat Autònoma de Barcelona)

Data:	2022
Resum:	This hypothesis proposal addresses three major questions: (1) Why do we need imaging biomarkers for assessing the efficacy of immune system participation in glioblastoma therapy response? (2) Why are they not available yet? and (3) How can we produce them? We summarize the literature data supporting the claim that the immune system is behind the efficacy of most successful glioblastoma therapies but, unfortunately, there are no current short-term imaging biomarkers of its activity. We also discuss how using an immunocompetent murine model of glioblastoma, allowing the cure of mice and the generation of immune memory, provides a suitable framework for glioblastoma therapy response biomarker studies. Both magnetic resonance imaging and magnetic resonance-based metabolomic data (i. e. , magnetic resonance spectroscopic imaging) can provide non-invasive assessments of such a system. A predictor based in nosological images, generated from magnetic resonance spectroscopic imaging analyses and their oscillatory patterns, should be translational to clinics. We also review hurdles that may explain why such an oscillatory biomarker was not reported in previous imaging glioblastoma work. Single shot explorations that neglect short-term oscillatory behavior derived from immune system attack on tumors may mislead actual response extent detection. Finally, we consider improvements required to properly predict immune system-mediated early response (1-2 weeks) to therapy. The sensible use of improved biomarkers may enable translatable evidence-based therapeutic protocols, with the possibility of extending preclinical results to human patients.
Ajuts:	Agencia Estatal de Investigación PID2020-113058GB-I00 European Commission. Horizon 2020 813120 Ministerio de Sanidad y Consumo CB06/01/0010 European Commission. Horizon 2020 777222
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; Versió publicada
Matèria:	Glioblastoma ; Cancer immune cycle ; Immunotherapy ; Host immune system ; Magnetic resonance spectroscopic imaging ; Metabolomics ; Imaging biomarker
Publicat a:	Metabolites, Vol. 12 Núm. 3 (2022) , p. 243, ISSN 2218-1989

DOI: 10.3390/metabo12030243
PMID: 35323686

23 p, 1.8 MB

El registre apareix a les col·leccions:
Articles > Articles publicats